- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05879510
68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients with renal masses scheduled for surgical resection. Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed. Additionally, prior to resection of the tumor, contrast-enhanced CT imaging of the abdomen, and if clinically warranted, or as part of the local standard of care, of the chest, will be performed. Both imaging modalities will be performed prior to resection of the kidney(s). PET/CT studies will be interpreted by two readers and diagnostic CT will be interpreted by one reader, all of whom will provide independent and blinded interpretations. Imaging interpretations and histopathologic evaluation data will be used to estimate the sensitivity, specificity, and predictive value (primary and secondary objectives) of each modality. The exploration into the detection of metastases by 68Ga-NY104 PET/CT in comparison to diagnostic CT will also be performed.
The pathologist will identify representative tumor tissue for the determination of histology, grading, and CAIX expression.
63 patients will be recruited in Peking Union Medical College Hospital. This study will be conducted according to local regulations and laws, the ethical principles that have their origin in the Declaration of Helsinki, and the principles of Good Clinical Practice.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Li Huo, MD
- Phone Number: 18612672038
- Email: huoli@pumch.cn
Study Contact Backup
- Name: Wenjia Zhu, MD
- Phone Number: 18614080164
- Email: zhuwenjia_pumc@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Wenjia Zhu, MD
- Email: zhuwenjia_pumc@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 y
- Presence of a renal mass
- Scheduled for surgical resection of renal mass (partial or total nephrectomy, open, laparoscopic, or robot-assisted technique)
- Expected survival of at least 3 months
- ECOG ≤ 2
- Written informed consent provided for participation in the trial
- In the opinion of investigator, willing and able to comply with required study procedures.
Exclusion Criteria:
- On VEGF TKI treatment less than 1 week before 68Ga-NY104 PET/CT. TKI is known to affect girentuximab binding in patients with ccRCC and is expected to have the same effect on 68Ga-NY104. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NY104 PET/CT is required.
- Intercurrent medical condition that renders the patient ineligible for surgery.
- Pregnancy or breastfeeding.
- Severe claustrophobia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 68Ga-NY104 PET/CT
Each patient will receive one dose of 68Ga-NY104 by intravenous route.
Dedicated whole-body PET/CT imaging will be performed.
|
Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binary reading of renal lesions identified on 68Ga-NY104 PET/CT
Time Frame: From study completion to 1 month after completion
|
Define lesion as PET positive or PET negative lesion.
The kidney lesion is designated as positive if the SUVmax of kidney lesions is higher than that of liver (reference).
|
From study completion to 1 month after completion
|
Histological classification of operated renal lesions
Time Frame: From study completion to 1 month after completion
|
The histological classification of operated renal lesions will be determined according to WHO classification of tumors, Feb 2004.
|
From study completion to 1 month after completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SUVmax of liver uptake on 68Ga-NY104 PET/CT
Time Frame: From study completion to 1 month after completion
|
The liver uptake (SUVmax (liver)) is used as the references to define PET positive lesions.
It is measured by placing a 3-cm region of interest in right lobe at the level of porta hepatis.
Focal lesion should be avoided if present.
|
From study completion to 1 month after completion
|
Intensity of CAIX staining of operated renal lesions
Time Frame: From study completion to 1 month after completion
|
The intensity of CAIX staining of operated renal lesions will be based on a 4-point scale from 0-3 according to the method of Bui et al, 2003
|
From study completion to 1 month after completion
|
Binary reading of renal lesions identified on diagnostic CT
Time Frame: From study completion to 1 month after completion
|
A tumor will be described as clear cell renal carcinoma on a triphasic CT if one of the following two parameters is applicable:
|
From study completion to 1 month after completion
|
Size of renal lesions identified on diagnostic CT
Time Frame: From study completion to 1 month after completion
|
The longest diameter of the tumor will be measured on diagnostic CT
|
From study completion to 1 month after completion
|
Number of metastatic lesions identified on 68Ga-NY104 PET/CT
Time Frame: From study completion to 1 month after completion
|
For metastasis evaluation, any focal accumulation of 68Ga-NY104 outside the kidneys that cannot be explained by physiologic uptake is interpreted as focal lesion.
The SUVmax and tumor-to-background should be evaluated.
Surrounding tissue is the preferred background tissue.
Should not available, the blood pool should be designated as background tissue.
Any focal lesion identified on 68Ga-NY104 PET will be considered to be positive for metastasis if SUVmax (lesion) is no less than SUVmax (liver) or tumor-to-background ratio is higher than 1.
|
From study completion to 1 month after completion
|
Szie of metastatic lesions identified on 68Ga-NY104 PET/CT
Time Frame: From study completion to 1 month after completion
|
For metastasis evaluation, any focal accumulation of 68Ga-NY104 outside the kidneys that cannot be explained by physiologic uptake is interpreted as focal lesion.
The SUVmax and tumor-to-background should be evaluated.
Surrounding tissue is the preferred background tissue.
Should not available, the blood pool should be designated as background tissue.
Any focal lesion identified on 68Ga-NY104 PET will be considered to be positive for metastasis if SUVmax (lesion) is no less than SUVmax (liver) or tumor-to-background ratio is higher than 1.
|
From study completion to 1 month after completion
|
SUVmax of renal lesions identified on 68Ga-NY104 PET/CT
Time Frame: From study completion to 1 month after completion
|
For kidney lesions, the tracer uptake is quantified using maximal standard uptake value (SUVmax) by drawing a 3-dimensional region of interest (ROI) over the lesion using a threshold of 40% SUVmax.
The ROI should be drawn with caution not to include any adjacent normal kidney parenchyma.
|
From study completion to 1 month after completion
|
Tumor grade of operated renal lesions
Time Frame: From study completion to 1 month after completion
|
The tumor grade of operated renal lesions will be determined according to Fuhrmann grading system
|
From study completion to 1 month after completion
|
Extent of CAIX staining of operated renal lesions
Time Frame: From study completion to 1 month after completion
|
The extent of CAIX staining of operated renal lesions will be determined by the percentage of the target tissue sample that have positive CAIX expression according to the method of Bui et al, 2003
|
From study completion to 1 month after completion
|
Location of metastatic lesions identified on 68Ga-NY104 PET/CT
Time Frame: From study completion to 1 month after completion
|
For metastasis evaluation, any focal accumulation of 68Ga-NY104 outside the kidneys that cannot be explained by physiologic uptake is interpreted as focal lesion.
The SUVmax and tumor-to-background should be evaluated.
Surrounding tissue is the preferred background tissue.
Should not available, the blood pool should be designated as background tissue.
Any focal lesion identified on 68Ga-NY104 PET will be considered to be positive for metastasis if SUVmax (lesion) is no less than SUVmax (liver) or tumor-to-background ratio is higher than 1.
|
From study completion to 1 month after completion
|
Number of metastatic lesions on diagnostic CT
Time Frame: From study completion to 1 month after completion
|
The number of metastatic lesions on diagnostic CT will be determined by radiologist according to the typical location, enhancement pattern of the lesions.
|
From study completion to 1 month after completion
|
Location of metastatic lesions on diagnostic CT
Time Frame: From study completion to 1 month after completion
|
The number of metastatic lesions on diagnostic CT will be determined by radiologist according to the typical location, enhancement pattern of the lesions.
|
From study completion to 1 month after completion
|
Size of metastatic lesions on diagnostic CT
Time Frame: From study completion to 1 month after completion
|
The number of metastatic lesions on diagnostic CT will be determined by radiologist according to the typical location, enhancement pattern of the lesions.
|
From study completion to 1 month after completion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Li Huo, MD, Peking Uion Medical College Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
Other Study ID Numbers
- NYCRPS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
Queen Mary University of LondonAstraZeneca; Vall d'Hebron Institute of OncologyActive, not recruitingRenal Clear Cell Carcinoma | Renal Papillary Cell CarcinomaUnited Kingdom
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Clear Cell Renal Cell Carcinoma
-
University of WashingtonMerck Sharp & Dohme LLC; Prometheus LaboratoriesTerminatedMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8United States
Clinical Trials on 68Ga-NY104 PET/CT
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruitingMetastatic Clear Cell Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
Affiliated Hospital of Jiangnan UniversityRecruiting
-
Jonsson Comprehensive Cancer CenterCompletedNeuroendocrine CarcinomaUnited States
-
Peking Union Medical College HospitalCompletedClear Cell Renal Cell CarcinomaChina
-
The First Affiliated Hospital of Xiamen UniversityRecruitingPrimary MyelofibrosisChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedAtheroscleroses, CoronaryNetherlands
-
Peking University Cancer Hospital & InstituteCompleted